{"nctId":"NCT00363896","briefTitle":"A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2006-07"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":843,"armGroups":[{"label":"Aclidinium 200 μg once-daily","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD\n\nExclusion Criteria:\n\n* History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough FEV1 (L) at 28 Weeks on Treatment","description":"Trough FEV1 (mean of two highest FEV1 values assessed at 23 and 24 hours after inhalation) at 28 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.422","spread":"0.011"},{"groupId":"OG001","value":"1.356","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate or Severe COPD Exacerbation at 52 Weeks on Treatment","description":"Time to first moderate or severe exacerbation:\n\nIncrease of COPD symptoms during at least 2 consecutive days, treated with antibiotics and/or systemic corticosteroids or an increase in dose of systemic corticosteroids, or leading to hospitalisation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at 52 Weeks on Treatment","description":"Percentage of patients who achieved a clinically relevant improvement in health-related quality of life at 52 weeks, as measured by at least a 4-unit decrease from baseline in St George's Respiratory Questionnaire (SGRQ) total score","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":null},{"groupId":"OG001","value":"60.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in the First Second (FEV1) (L) at 12 Weeks on Treatment","description":"Trough FEV1 (mean of two highest FEV1 values assessed at 23 and 24 hours after inhalation) at 12 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.428","spread":"0.010"},{"groupId":"OG001","value":"1.366","spread":"0.016"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":50,"n":627},"commonTop":["Nasopharyngitis","Headache","Back pain","Cough"]}}}